Tobias Polak

Incremental benefits of novel pharmaceuticals in the United Kingdom 71 4♣ Part B: Example of various redaction strategies 1 Complete redaction Supplementary Figure 1: Completely redacted estimates (ICER, QALY, cost) from TA401: Bosutinib for previously treated chronic myeloid leukaemia. Table from Evidence Review Group Report. Supplementary Figure 2: Completely redacted estimates (ICER, QALY, cost) from TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer. Table from Evidence Review Group Report.

RkJQdWJsaXNoZXIy MTk4NDMw